Vector Analytics and Potency Assays Patents: Who Leads and Where Claims Are Open
Concentrated but not closed. The top 5 assignees hold 34.7% of all 2,327 records in scope, and the top 10 hold 50.6% — leaving roughly half the field to a long tail of single- and few-filing entrants. Filings reached 125 in 2017 and peaked at 212 in 2018. The count of 12 in 2026 reflects the partial year and roughly 18-month publication lag rather than a drop in filing activity — the reliable comparison is 2021 (102) to 2024 (122), a 20% rise.
- 1GENENTECH INC252
- 2F HOFFMANN LA ROCHE & CO AG186
- 3PFIZER INC131
- 4ABLYNX NV125
- 5GENZYME CORP113
See the full vector analytics and potency assays analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in vector genome titer and potency assay methods?
The assignee ranking in this dataset is led by a single filer with 252 records, well ahead of the fifth-placed company at 113. The top 10 assignees together account for 50.6% of all 2,327 records in scope, so while the field has a clear leader, half of all filing activity sits outside that top tier. Anyone assessing freedom to operate should look beyond the top few names, since the long tail includes universities and mid-size biologics firms with meaningful individual portfolios.
Is patent filing in this space still growing or has it peaked?
Filing peaked in 2018 at 212 records and has settled at a lower but still substantial level since. The reliable recent comparison is 2021 to 2024, where filings rose 20% from 102 to 122 — the most recent year the dataset treats as complete. Years after 2024 show lower counts, but that reflects the roughly 18-month lag between filing and publication, not a genuine decline in activity.
Where is the least crowded claim space in this field?
G01N, the IPC class covering material analysis and testing, appears on only 21.4% of the 2,327 records, compared with 66.4% for medicinal preparation claims under A61K. That gap suggests pure assay-methodology claims — digital PCR bridging, reference material standardisation, specification setting — carry lower filing density than vector composition claims, making them a reasonable area to scout for open space before drafting.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Vector Analytics and Potency Assays covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.